Opinion statement
Gastrointestinal stromal tumors (GISTs) are mesenchymal gut tumors that differ dramatically from other histologically similar neoplasms, such as leimomyomas, leiomyosarcomas (LMS), and neural tumors. Complete surgical removal remains the best current therapy for GISTs, but even major resections are associated with recurrence in approximately 90% of cases. GISTs are remarkably resistant to irradiation and standard chemotherapy; there is no role for treatment with those modalities. Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60% and overall tumor control rates of 85%. Selected groups of patients, as based on tumor mutational status, have response rates as high as 80%. To date, STI571 therapy remains the only systemic treatment for GISTs to have meaningful clinical activity. Though other molecularly targeted therapies exist in oncology (eg, trastuzumab), STI571 is one of the first that applies a drug specifically designed to inhibit the product of a constitutively-activating mutation that drives pathogenesis of a solid tumor. Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Miettinen M, Lasota J: Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2000, 438:1–12. Thorough review of the biologic features of GISTs.
Suster S: Gastrointestinal stromal tumors. Semin Diagn Pathol 1996, 13:297–313.
Plaat BEC, Hollema H, Molenaar WM, et al.: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000, 18:3211–3220. Comparison of GISTs and standard leiomyosarcomas.
Hirota H, Isozaki K, Moriyama Y, et al.: Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577–580. A basic science classic that details the role of activating c-kit mutation in GISTs.
Conlon KC, Casper ES, Brennan MF: Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surgical Oncol 1995, 2:26–31.
Lindsay PC, Ordonez N, Raaf JH: Gastric leiomyosarcoma: clinical and pathological review of fifty patients. J Surg Oncol 1981, 18:399–421.
DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51–58. Excellent single institutional surgical review of confirmed GIST.
Ng EH, Pollock RE, Munsel MF, et al.: Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992, 215:68–77. Large series with long-term follow up of GIST patients, including presentation with metastatic and locally recurrent disease.
McGrath PC, Neifeld JP, Lawrence WJ, et al.: Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987, 206:706–710.
Shiu MH, Farr GH, Papachristou DN, et al.: Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982, 49:177–187.
Akwari OE, Dozois RR, Weiland LH, et al.: Leiomyosarcoma of the small and large bowel. Cancer 1978, 42:1375–1384.
Edmonson J, Marks R, Buckner J, et al.: Contrast of D-MAP + sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Am Soc Clin Oncol 1999, 18:541a [abstract 2088]. The first major study to separate GISTs from muscle tumors. It carefully details response rates to sarcoma-oriented chemotherapy.
Blanke CD, von Mehren M, Joensuu H, et al.: Evaluation of the safety and efficacy of an oral molecularlytargeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit (CD117). Proc Am Soc Clin Oncol 2001, 20:1a [abstract 1]. The largest reported treatment series to feature GIST patients only.
Heinrich MC, Griffith DJ, Druker BJ, et al.: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925–32. Detailed description of the effect of STI571 on wild-type and mutated c-Kit.
Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052–1056. The first description of an effective systemic therapy in GISTs.
Van Oosterom AT, Judson I, Verweij J, et al.: STI571, an active drug in metastatic gastrointestinal stromal tumors, an EORTC phase I study. Proc Am Soc Clin Oncol 2001, 20:1a [abstract 2]. Phase I trial of STI571 in KIT+ GIST and other soft tissue sarcomas.
Pollock J, Morgan D, Denobile J, et al.: Adjuvant radiotherapy for gastrointestinal stromal tumor of the rectum. Dig Dis Sci 2001, 46:268–272.
Shioyama Y, Yakeishi Y, Watanabe T, et al.: Long-term control for a retroperitoneal metastasis of malignant gastrointestinal stromal tumor after chemoradiotherapy and immunotherapy. Acta Oncol 2001, 40:102–104.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blanke, C.D., Eisenberg, B.L. & Heinrich, M.C. Gastrointestinal stromal tumors. Curr. Treat. Options in Oncol. 2, 485–491 (2001). https://doi.org/10.1007/s11864-001-0070-0
Issue Date:
DOI: https://doi.org/10.1007/s11864-001-0070-0